These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32844821)

  • 21. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
    Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
    Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
    Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
    Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
    Jensen JD; Lynch M
    Heredity (Edinb); 2020 May; 124(5):619-620. PubMed ID: 32251365
    [No Abstract]   [Full Text] [Related]  

  • 31. Coronavirus Disease 2019: Clinical Review.
    Gouveia CC; Campos L
    Acta Med Port; 2020 Jul; 33(7-8):505-511. PubMed ID: 32498762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.
    Kutlu Ö; Yılmaz Ş
    Photodermatol Photoimmunol Photomed; 2021 Jul; 37(4):343-344. PubMed ID: 33480085
    [No Abstract]   [Full Text] [Related]  

  • 33. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
    Manabe T; Kambayashi D; Akatsu H; Kudo K
    BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence.
    Khambholja K; Asudani D
    Travel Med Infect Dis; 2020; 35():101710. PubMed ID: 32360327
    [No Abstract]   [Full Text] [Related]  

  • 37. Advances and challenges in the prevention and treatment of COVID-19.
    Han YJ; Ren ZG; Li XX; Yan JL; Ma CY; Wu DD; Ji XY
    Int J Med Sci; 2020; 17(12):1803-1810. PubMed ID: 32714083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outbreak of COVID-19: An emerging global pandemic threat.
    Peng M
    Biomed Pharmacother; 2020 Sep; 129():110499. PubMed ID: 32768974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of favipiravir on hematological parameters of covıd-19 patients.
    Yaylaci S; Dheir H; Şenocak D; Genc AB; Kocayigit H; Çekiç D; Varım C; Aydın A; Koroglu M; Karabay O
    Rev Assoc Med Bras (1992); 2020; 66Suppl 2(Suppl 2):65-70. PubMed ID: 32965359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.